Eric Morand
Monash University
H-index: 76
Oceania-Australia
Top articles of Eric Morand
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Systemic glucocorticoid therapy for SLE | Champa Nataraja Eric Morand Anselm Mak | 2025/1/1 | |
Treatment of flares in lupus | 2024/1/25 | ||
Preclinical evidence for the glucocorticoid-sparing potential of a dual toll-like receptor 7/8 inhibitor in autoimmune diseases | Journal of Pharmacology and Experimental Therapeutics | Ankita Deshmukh Albertina Pereira Nicholas Geraci Evgeni Tzvetkov Melinda Przetak | 2024/3/1 |
P165 Kinetics of mucocutaneous and musculoskeletal responses to deucravacitinib in patients with systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial | Ronald F van Vollenhoven Joseph F Merola Kathryn H Dao Piotr Leszczynski Marilyn Pike | 2024/3/1 | |
Autoimmune Rheumatic Diseases in Australian Aboriginal and Torres Strait Islander Peoples: What Do We Know? | Laura E Eades Jason Sines Alberta Y Hoi Ruaidhri Liddle Rangi Kandane-Rathnayake | 2024/1/14 | |
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a … | Annals of the Rheumatic Diseases | Yasuhiro Katsumata Eisuke Inoue Masayoshi Harigai Jiacai Cho Worawit Louthrenoo | 2024/2/29 |
P54 Screening for primary aldosteronism in hypertensive patients with systemic lupus erythematosus: are we doing it enough? | Matthew Wong Alberta Y Hoi Joanna R Kent Eric F Morand Jun Yang | 2024/3/1 | |
Predictors of organ damage in Systemic Lupus Erythematosus in the Asia Pacific region: A systematic review | Arushi Ramnarain Christy Liam Dominique Milea Eric Morand Joanna Kent | 2024/1/8 | |
Smith-specific regulatory T cells halt the progression of lupus nephritis | Nature Communications | Peter J Eggenhuizen Rachel MY Cheong Cecilia Lo Janet Chang Boaz H Ng | 2024/2/6 |
LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis | Ronald van Vollenhoven Eric Morand Richard Furie Kenneth Kalunian Raj Tummala | 2024/3/1 | |
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis … | Annals of the Rheumatic Diseases | Tina Baker Hoda Sharifian Paul J Newcombe Patrick G Gavin Mark N Lazarus | 2024/4/3 |
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update | GK Bertsias JPA Ioannidis M Aringer E Bollen Stefano Bombardieri | 2010/12/1 | |
SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus—an analysis of anti-double-stranded DNA monitoring | Rheumatology | Ai Li Yeo Rangi Kandane-Rathnayake Rachel Koelmeyer Vera Golder Worawit Louthrenoo | 2024/2/1 |
O32 Impact of patient baseline characteristics on SLE Responder Index-4 (SRI [4]) responses to deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 … | Eric Morand Cristina Arriens Laura Geraldino-Pardilla Ann E Clarke Samantha Pomponi | 2024/3/1 | |
OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set | Seminars in arthritis and rheumatism | Wils Nielsen Vibeke Strand Lee S Simon Ioannis Parodis Alfred HJ Kim | 2024/4/1 |
Local Ancestry at the Major Histocompatibility Complex Region is Not a Major Contributor to Disease Heterogeneity in a Multiethnic Lupus Cohort | Arthritis & Rheumatology | Olivia Solomon Cristina M Lanata Cameron Adams Joanne Nititham Kimberly E Taylor | 2024/1/30 |
Flare in Systemic Lupus Erythematosus: Lost in Translation? | Eric F Morand Sarah A Jones | 2024/3/1 | |
TYK2: an emerging therapeutic target in rheumatic disease | Eric Morand Joseph F Merola Yoshiya Tanaka Dafna Gladman Roy Fleischmann | 2024/3/11 | |
Fibromyalgia, mood disorders, cognitive test results, cognitive symptoms and quality of life in systemic lupus erythematosus | Rheumatology | Sudha Raghunath Emma K Guymer Yifat Glikmann-Johnston Vera Golder Rangi Kandane Rathnayake | 2023/1/1 |
Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized … | SKIN The Journal of Cutaneous Medicine | Victoria Werth Marilyn Pike Joan Merrill Eric Morand Ronald van Vollenhoven | 2023/3/13 |
Co-Authors
